Ceapro (CRPOF) News Today $0.17 0.00 (0.00%) (As of 06/6/2024) Add Compare Share Share Headlines Stock AnalysisEarnings All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Aeterna Zentaris and Ceapro Complete Merger TransactionJune 3, 2024 | globenewswire.comCeapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate UpdateMay 29, 2024 | globenewswire.comCeapro Inc. Reports 2023 Financial Results and Operational HighlightsApril 29, 2024 | globenewswire.comAeterna Zentaris Inc: Ceapro Receives Final Court Approval for Merger with Aeterna ZentarisMarch 28, 2024 | finanznachrichten.deCeapro Receives Final Court Approval for Merger with Aeterna ZentarisMarch 28, 2024 | globenewswire.comAeterna Zentaris and Ceapro Merger Approved by Securityholders at Special MeetingsMarch 12, 2024 | globenewswire.comLeading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical CompanyFebruary 26, 2024 | globenewswire.comCeapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base BusinessFebruary 23, 2024 | globenewswire.comCeapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna ZentarisFebruary 15, 2024 | globenewswire.comCeapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based DiseasesDecember 13, 2023 | finance.yahoo.comCeapro GAAP EPS of -C$0.01, revenue of C$2.62MNovember 29, 2023 | msn.comCeapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) TechnologyNovember 7, 2023 | finance.yahoo.comCeapro Announces Next Phase of Research Collaboration with the Angiogenesis FoundationJuly 18, 2023 | finance.yahoo.comCeapro Inc.: Ceapro Announces Results of 2023 Shareholders' MeetingJune 7, 2023 | finanznachrichten.deCeapro Announces Results of 2023 Shareholders’ MeetingJune 7, 2023 | finance.yahoo.comCeapro Inc. Appoints Michel Regnier as Senior Vice President, Technical OperationsApril 27, 2023 | finance.yahoo.comClosing Bell: Ceapro Inc flat on Tuesday (CZO)April 26, 2023 | theglobeandmail.comClosing Bell: Ceapro Inc flat on Monday (CZO)April 25, 2023 | theglobeandmail.comClosing Bell: Ceapro Inc down on Thursday (CZO)April 13, 2023 | theglobeandmail.comCeapro Announces Data from Research Collaboration with McMaster University to be Presented at the 2023 American Thoracic Society (ATS) International ConferenceMarch 23, 2023 | finance.yahoo.comCeapro Inc. (CRPOF) Stock Historical Prices & Data - Yahoo FinanceMarch 14, 2023 | finance.yahoo.comCeapro Announces Data from Research Collaboration with the Angiogenesis Foundation to be Presented at the 2023 Annual Meeting of the Wound Healing American SocietyMarch 8, 2023 | finance.yahoo.comCeapro Inc. Recognized as a Top 50 TSX Venture Exchange CompanyFebruary 21, 2023 | finance.yahoo.comCeapro to Present at the Virtual Investor 2023 Companies to Watch EventJanuary 10, 2023 | finance.yahoo.comCeapro receives approval to begin human trial for anti-inflammatory drugDecember 22, 2022 | msn.comCeapro Inc. Receives Approval from Health Canada to Commence Phase 1/2a Human Clinical Trial Assessing Avenanthramide TabletsDecember 22, 2022 | technews.tmcnet.comCeapro Inc. Reports 2022 Third Quarter and Nine-Month Financial Results and Operational HighlightsNovember 9, 2022 | finance.yahoo.comCeapro Inc. Launches Next Phase of Scale Up for its Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical MarketsNovember 7, 2022 | finance.yahoo.comCeapro Lone Stock at 52-Week HighAugust 26, 2022 | ca.finance.yahoo.comCeapro Inc. Expands Collaborative Research Program with McMaster University to Develop an Inhalable Immuno-Therapeutic/-Prophylactic for COVID-19-Induced Lung FibrosisAugust 11, 2022 | financialpost.comCeapro Inc. Announces Publication of Positive Results for PGX-Processed Alginates Impregnated with CoQ10 in The Journal of Supercritical FluidsAugust 9, 2022 | finance.yahoo.comCeapro Inc. to Present at the H.C. Wainwright Global Investment ConferenceMay 23, 2022 | finance.yahoo.comCeapro Inc. Present PGX Enabling Technology Case Study at the 13th International Symposium on Supercritical FluidsMay 13, 2022 | benzinga.comCeapro Signs Exclusive Long-Term Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, SymriseMarch 10, 2022 | financialpost.comCeapro Inc. to Present at the Virtual Investor 2022 Top Picks ConferenceJanuary 20, 2022 | benzinga.comCeapro Inc. Announces R&D Funding to Support PGX Technology ProjectNovember 29, 2021 | finance.yahoo.comCeapro Inc. Reports 2021 Third Quarter and Nine-Month Financial Results and Operational HighlightsNovember 17, 2021 | finance.yahoo.comCeapro Inc. Reports Preliminary Results from Clinical Trial Evaluating Oat Beta Glucan in Patients with High Cholesterol LevelsNovember 17, 2021 | finance.yahoo.comCeapro Inc. Provides Update on Development of an Inhalable Therapeutic Using Yeast Beta Glucan Processed with Pressurized Gas eXpanded Technology (PGX-YBG)November 11, 2021 | finance.yahoo.comCeapro Inc.'s (CVE:CZO) Has Performed Well But Fundamentals Look Varied: Is There A Clear Direction For The Stock?October 26, 2021 | finance.yahoo.comCeapro Inc. Reports 2021 Second Quarter and Six-Month Financial Results and Operational HighlightsAugust 26, 2021 | finance.yahoo.comCeapro Inc. Enters into Research Collaboration with the Angiogenesis Foundation for Beta Glucan ...August 24, 2021 | apnews.comGlobal Electric Vehicle Outlook 2021August 13, 2021 | au.finance.yahoo.com Get Ceapro News Delivered to You Automatically Sign up to receive the latest news and ratings for CRPOF and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now CRPOF Media Mentions By Week CRPOF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRPOF News Sentiment▼0.000.60▲Average Medical News Sentiment CRPOF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRPOF Articles This Week▼00▲CRPOF Articles Average Week Get Ceapro News Delivered to You Automatically Sign up to receive the latest news and ratings for CRPOF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MAIA Biotechnology News Virios Therapeutics News Prelude Therapeutics News Celularity News Kezar Life Sciences News Provectus Biopharmaceuticals News Rallybio News Exicure News CASI Pharmaceuticals News BioVie News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:CRPOF) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ceapro Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ceapro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
